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Vascular Closure Devices
The Second Decade
Harold L. Dauerman, MD, FACC,* Robert J. Applegate, MD, FACC,† David J. Cohen, MD, MSC‡
Burlington, Vermont; Winston-Salem, North Carolina; and Kansas City, Missouri
Vascular closure devices (VCDs) introduce a novel means for improving patient comfort and accelerating ambu-
lation after invasive cardiovascular procedures performed via femoral arterial access. Vascular closure devices
have provided simple, rapid, and reliable hemostasis in a variety of clinical settings. Despite more than a decade
of development, however, VCD utilization has neither been routine in the U.S. nor around the world. Their limited
adoption reflects concerns of higher costs for cardiac procedures and a lack of data confirming a significant re-
duction in vascular complications compared with manual compression. Recent data, however, suggest that VCD
are improving, complication rates associated with their use may be decreasing, and their utilization may im-
prove the process of care after femoral artery access. Challenges in the second decade of VCD experience will
include performing definitive randomized trials, evaluating outcomes in higher-risk patients, and developing
more ideal closure devices. (J Am Coll Cardiol 2007;50:1617–26) © 2007 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.07.028p
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tascular closure devices (VCDs) were first developed in the
id-1990s, largely propelled by concerns of high rates of
ccess site bleeding associated with percutaneous coronary
ntervention (PCI) procedures. Despite the goals of improv-
ng patient outcomes, patient comfort, and catheterization
aboratory efficiency (1,2), VCD adoption has not paralleled
he rapid pace of other interventional cardiology technolo-
ies (e.g., drug-eluting stents) (3). In an American College
f Cardiology-National Cardiovascular Data Registry
ACC-NCDR) analysis of 166,680 diagnostic catheteriza-
ion or PCI procedures performed in 2001, only one-third
f patients received a VCD (4). Despite the considerable
nowledge that has been gained in the past 10 years
egarding the strengths, weaknesses, and potential applica-
ions of VCD, concerns about costs of VCD use and lack of
uperiority over manual compression have dampened enthu-
iasm for their routine use. While VCD use is not routine,
he volume of VCD utilization in 2006 suggests that this
echnology is an important part of invasive cardiovascular
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ccepted July 15, 2007.rocedures in many institutions: over 2 million VCD were
old in 2006 (1.6 million in the U.S. and 0.5 million in
urope) with a market growth of 11% in the U.S. and 8%
n Europe (5). In this review, we will examine the evidence
ase concerning VCD use and comment on the challenges
acing more widespread adoption of VCD use in the next
ecade.
CDs: The First Decade
brief history. Vascular closure devices are in their second
ecade of development for diagnostic and interventional
ardiovascular procedures. The technologies approved from
995 to 1998 focused on active closure methods including
uture alone (2), extravascular collagen alone (6), and
uture-collagen combinations (1) (Fig. 1). Since their intro-
uction, the original devices (Perclose, Abbott Vascular,
edwood City, California; Angio-Seal, St. Jude Medical,
t. Paul, Minnesota) have undergone multiple iterations
hile maintaining their core concept (7). Recently, a con-
eptually different type of active-closure VCD involving
urgical staple/clip technology has also become available
StarClose, Abbott Vascular, Redwood City, California;
VS-Angiolink, Medtronic Co., Minneapolis, Minnesota)
8–10) (Fig. 2, Table 1). “Passive closure” technologies have
een developed in parallel with the active closure devices.
assive closure approaches have focused on enhanced man-
al compression utilizing external patches with prothrom-
otic coatings (Syvek Patch, Marine Polymer Technologies,
anvers, Massachusetts) (11,12), wire-stimulated track
hrombosis (Boomerang Wire, Cardiva Medical, Mounta-
nview, California) (13), or assisted compression with me-
t
h
o
a
(
l
i
a
p
l
i
t
m
h
c
p
a
V
r
P
a
r
p
c
i
l
n
d
I
C
W
w
g
t
t
s
c
p
a
(
F
S
t
i
d
i
r
c
l
v
i
(
(
s
w
f
1618 Dauerman et al. JACC Vol. 50, No. 17, 2007
VCD Utilization and Outcomes October 23, 2007:1617–26chanical clamps; the passive clo-
sure devices do not afford
immediate (5 min) hemostasis
(14,15) (Fig. 2). This review will
focus on the immediate, active
hemostasis closure devices given
their greater utilization over the
past decade.
The adoption of VCD has occurred because of a clear
echnological feat: VCD reliably shortens the time to
emostasis (elapsed time between sheath removal and first
bserved hemostasis) compared with manual compression
nd thus allows earlier patient ambulation (1,8,10,16,17)
Table 2). Alternative strategies for achieving early ambu-
ation are the use of smaller sheaths for diagnostic catheter-
zation as well as the use of the radial artery approach. The
dvantage of femoral vascular closure is that it can be
erformed immediately at the end of the procedure regard-
ess of anticoagulation status; procedural success is expected
n95% of patients, and time to hemostasis is generally less
han 5 min with Angio-Seal, Perclose, and staple/clip-
ediated VCD (1,2,10,18). This compares favorably with
emostasis times of 15 to 30 min with standard 6-F manual
ompression. In addition, sheath removal via manual com-
ression generally requires the operator to wait for the
ctivated clotting time to reach a level of 180 s (19), while
CD allows immediate removal of the femoral sheath
egardless of anticoagulation status. While length of stay for
CI patients will not necessarily be reduced by early
mbulation (unless same-day PCI is adopted), it can be
educed for diagnostic patients (2,16,20). And, for many
atients, VCD can allow improved patient satisfaction and
omfort related to the avoidance of prolonged sheath
nsertion and manual compression (19). Given this techno-
ogical feat, it may be somewhat surprising that VCD have
Figure 1 The First Decade of Vascular Closure Devices
The first decade of vascular closure devices according to their year of Food and
Drug Administration approval. During this transition from bare-metal to drug-
eluting stent eras, other factors may have influenced vascular complication
rates (i.e., percutaneous coronary intervention pharmacology). GP 
glycoprotein.
Abbreviations
and Acronyms
PCI  percutaneous
coronary intervention
VCD  vascular closure
devicemot become the standard of care for invasive cardiac proce-
ures (21).
ssues Challenging VCD Adoption:
omplications and Cost
hat is the current rate of vascular complications associated
ith VCD? Vascular closure device pivotal studies have
enerally included 250 to 600 randomized patients. Given
heir limited sample sizes, such studies can reliably identify
hose complications that occur in 3% to 5% of the highly
elected subjects enrolled in the trials (1,2,8,10,22). Vascular
losure device trials have not been expanded to higher-risk
atient cohorts; thus, there is a lengthy list of precautions
nd warnings on the instructions for use for each device
Table 1). For example, in the randomized trial leading to
ood and Drug Administration (FDA) approval of the
tarClose nitinol clip system for diagnostic cardiac cathe-
erization, the list of angiographic and clinical exclusions
ncluded obesity, small femoral artery diameters, bleeding
iatheses, femoral arterial disease, and nonfemoral sheath
nsertion (20).
There are concerns that the VCD may cause increased
ates of rare complications, primarily based upon anecdotal
ase reports. Infections, femoral artery compromise, arterial
aceration, uncontrolled bleeding, pseudoaneurysm, atrio-
entricular fistula, as well as device embolism and limb
schemia have all been reported after VCD utilization
4,23). These reports span all VCD types including Perclose
24,25), Angio-Seal (26), and StarClose (27). One study
uggests that the severity of individual complications may be
orse after VCD use compared with manual compression
or PCI patients as VCDs are deployed at the point of
Figure 2 Overview of Vascular Closure Device Types
Vascular closure methods are: 1) passive and delayed—manual compression
with assistance (Femostop) or enhancement (patches); and 2) active and
immediate—collagen-based with or without anchor and suture, suture-based,
and staple/clip-mediated.aximal anticoagulation while manual compression is de-
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October 23, 2007:1617–26 VCD Utilization and Outcomesayed (27). Thus, the severity of bleeding complications
when they occur) would be expected to be greater with
CD than manual compression.
Reports of adverse events after VCD use prompted the
DA to initiate the largest study of 166,680 patients via the
CC-NDR database “to assess the relative risk of compli-
ations after the use of the 2 main types of hemostasis
evice” (4). However, concerns that VCD outcomes are
orse in comparison with manual compression are not
upported by review of published meta-analyses, multicenter
egistries, and longitudinal registries (Table 3). These stud-
es evaluated a larger number of patients than were studied
n the pivotal trials, but are limited by variable study end
oints. Some studies use a composite end point (4,7,17,22,
ndications, Contraindications,nd Cautions for 3 VCDs
Table 1 Indications, Contraindications,and Cautions for 3 VCDs
Angio-Seal* Perclose† StarClose†
Closure indication
Diagnostic cath   
PCI   
5-F sheath NM  
6-F sheath   
7-F sheath   No
8-F sheath   No
Ipsilateral access 90 days 1 cm higher No restriction‡ Not indicated
MRI safe NM NM 
Contraindication None None None
Warnings: “Do not use if . . .”
SFA or Profunda insertion   
Bifurcation insertion   
Above inguinal ligament   
Posterior wall puncture NM  
Multiple punctures NM  
Precautions: “Safety and
effectiveness of the VCD
has not been
established if . . .”
Patient on warfarin  NM NM
Inflammatory disease   
Morbid obesity NM  
Thrombolysis  NM NM
Access via vascular graft   
Significant PVD   
Uncontrolled HTN  NM 
Bleeding diathesis   
Ipsilateral venous sheath NM  
Femoral artery calcium NM  
Small femoral artery size   
Iliofemoral stenosis 50% NM  
Use of GP IIb/IIIa inhibitor NM  NM
Instructions for Use Angio-Seal VIP; St. Jude Medical February 2006 (www.sjm.com); †Instruc-
ions for Use Perclose A*T (August 2006) and StarClose (February 2007). Abbott Vascular
www.abbottvascular.com/ifu); ‡no restriction is only for reaccess after prior arteriotomy repaired
ith Perclose.
cath  catheterization; GP  glycoprotein; HTN  hypertension; MRI  magnetic resonance
maging; NM  not mentioned in instruction for use as indication, warning, or caution; PCI 
ercutaneous coronary intervention; PVD peripheral vascular disease; SFA superficial femoral
rtery; VCD vascular closure device; explicitly mentioned in instruction for use as indication,
arning, or caution.8–34), some studies use a single end point, (16,35,36), and aome studies define “vascular complications” differently
37). Nevertheless, there are several conclusions that may be
rawn from these larger studies of vascular complications:
Among patients undergoing diagnostic cardiac catheter-
ization, there is a 0.5% to 1.7% rate of vascular compli-
cations (4,7,16,31,34,38); this risk is not consistently
increased or decreased by VCD usage across all studies;
the largest study, from the ACC-NCDR, suggested a signif-
icant decrease in complications with VCD usage compared
with manual compression (4); it is possible this reduction
in complications is directly related to the VCD or
alternatively reflects a reluctance by the operator to use a
VCD in patients who are already having a complication
at the completion of the diagnostic procedure or in
circumstances where both VCD use and manual com-
pression have been associated with increased complica-
tions (e.g., high or low femoral insertion sites).
Among patients undergoing PCI, there is a 0.8% to 5.5%
rate of heterogeneously defined vascular complications;
with the exception of Vasoseal, there are no data to
clearly suggest an increased risk of vascular complications
with VCD use (4,29,33); some studies suggest that
VCDs decrease complications compared with manual
compression (17,33,34,36), some studies suggest poten-
tially increased risk with VCD (22,28,30), and some
suggest complication rates are similar (7,29,31,35); the
ACC-NCDR study suggests a nonsignificant reduction
in complications with VCD as compared with manual
compression for patients undergoing PCI (4).
iven the equipoise with respect to vascular complications
uggested by overview of these many VCD studies, it is not
urprising that manual compression has remained the most
ommon method for achieving hemostasis after invasive
ardiac procedures both in the U.S. and worldwide (4,8)
Fig. 2). An example of this practice pattern can be seen in
he TARGET (Comparison of 2 Platelet Glycoprotein IIb/
IIa Inhibitors, Tirofiban and Abciximab, for the Prevention of
schemic Events With Percutaneous Coronary Revasculariza-
ion) trial comparing abciximab to tirofiban. Of 4,809 patients
ndergoing PCI, 4,736 had femoral access. Use of VCD was
eft to the discretion of investigators—only 20% (n  985)
ere treated with a VCD (35). While the interventional
ardiology community has been noted for its aggressive adop-
ion of new technologies beyond FDA labeling and random-
zed clinical trial conclusions (3), VCD utilization demon-
trates the critical perspective that hospitals and interventional
ardiologists do bring to adoption of new technology.
actors Affecting Vascular Complication Rates:
atient Selection, Newer Anticoagulation, and
ntiplatelet Strategies and Device Improvements
ccurate estimation of the relative benefits of VCD versus
anual compression should also reflect what appears to be
change in the incidence of vascular complications in the
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VCD Utilization and Outcomes October 23, 2007:1617–26urrent era. In studies from the 1990s, vascular and bleeding
omplications after PCI were frequently in the 3% to 6%
ange (17,28,30,39,40). Recently, rates of major vascular
omplications after PCI are estimated at closer to 2%
4,40,41) (Fig. 3). This observation is supported by data
rom the PCI Registry of the Northern New England
ardiovascular Study Group. Using a standard definition of
ajor vascular complications (arterial injury and/or arterial-
Efficacy of VCDs for Reducing Time to Hemosta
Table 2 Efficacy of VCDs for Reducing Time
CLIP Study Diagnostic Arm—ITT
StarC
(n 
Procedure success (%) 100 (13
Mean time to hemostasis (min) 1.5 (
Mean time to ambulation (min) 162 (
Major complications (% patient-based) 0 (0/
Minor complications (% patient-based) 2.2 (3/
Mean time to dischargeability (h) 3.5 (
CLIP Study Interventional Arm—ITT
StarC
(n 
Procedure success (%) 98
Mean time to hemostasis (min) 8.0 (
Mean time to ambulation (min) 411 (
Major complications (% patient-based) 1.1 (2/
Minor complications (% patient-based) 4.3 (8/
ITT  intention to treat; VCD  vascular closure device.
elected Studies of VCDs as Compared With Manual Compression
Table 3 Selected Studies of VCDs as Compared With Manual C
Study Study Type n Device Compa
Cura et al. (28) Registry 2,918 VCD vs. MC
Dangas et al. (30) Registry 5,093 VCD vs. MC
Resnic et al. (17) Registry 3,027 VCD vs. MC
Dangas et al. (22)† Pooled randomized trials 2,095 VCD vs. MC
Tavris et al. (4)† ACC-NCDR 166,680 VCD vs. MC
Exaire et al. (35) TARGET trial substudy 4,736 VCD vs. MC
Koreny et al. (16)† Meta-analysis 4,000 VCD vs. MC
Vaitkus et al. (33)† Meta-analysis 5,045 VCD vs. MC
Nikolsky et al. (29) Meta-analysis 37,066 VCD vs. MC
Applegate et al. (7) Registry 4,699 Angio-Seal vs.
Arora et al. (34)† Registry 12,937 VCD vs. MCVascular complication may be defined differently for each study; †data include both diagnostic and inte
ACC-NCDR  American College of Cardiology-National Cardiovascular Data Registry; MC  manual comnjury-related bleeding), there has been a 42% relative
ecrease in complications from 2002 to 2006 (p  0.001)
D.J. Malenka and W.D. Piper, personal communication,
anuary 2007) (40). Changes in the characteristics of pa-
ients undergoing PCI do not appear to account for this
eduction in complications, since the major known risk
actors for vascular complications have remained constant
uring this period—advanced age (39,40), vascular disease
LIP Randomized Trial
emostasis: CLIP Randomized Trial
Standard Compression
(n  72) p Value
) 100 (72/72) NA
15.5 ( 11.4) 0.001
269.3 ( 134.8) 0.001
0 (0/72) —
1.4% (1/72) 1.000
5.2 ( 2.1) 0.001
Standard Compression
(n  91) p Value
98.7 NA
29.1 ( 35.3) 0.001
) 466 ( 257.2) 0.137
1.1 (1/91) 1.000
9.9 (9/91) 0.107
atients Undergoing PCI
ression for Patients Undergoing PCI
End Point Outcomes
Vascular complication* Angio-Seal 2.9%
Perclose 3.2%
MC 3.1%
p  NS
Surgical repair VCD 2.5%
MC 1.5%
p  0.03
Vascular complication MC 5.5%
VCD 3.0%
p  0.002
Device complications VCD 8.5%
MC 5.9%
p  0.02
Vascular complication 1.05% to 1.48% VCD
1.70% for MC
p  0.001
Transfusions VCD 1.0%
MC 0.8%
p  NS
Hematoma RR 1.14 for VCD (0.86–1.51)
Vascular complication RR 0.89 for VCD (0.86–0.91)
Increased risk for Vasoseal
Vascular complication p  0.06 for Angio-Seal benefit compared with MC
Increased risk for Vasoseal
Vascular complication Angio-Seal 1.5%
MC 1.7%
p  NS
Vascular complication 42% to 58% reduction in vascular complications
with VCD vs. MCsis: C
to H
lose
136)
6/136
4.5)
104.6)
136)
136)
2.1)
lose
184)
.9
28.2)
297.3
184)
184)for P
omp
rison
MCrventional cardiac procedures.
pression; RR  relative risk; other abbreviations as in Table 1.
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October 23, 2007:1617–26 VCD Utilization and Outcomes4,7,40), female gender (4,40), emergent procedures (4,40),
nd low body surface area (7,40). The reasons for the decrease
n vascular complications possibly reflects the influence of
everal factors: better patient selection for VCD, improved
emoral access techniques, changing PCI pharmacology, im-
roved VCD, and improved operator experience with VCD
se (32).
atient selection. Routine femoral angiography at the end
f the catheterization procedure is a significant advance
42–44). Such angiography allows identification of the
ajor risk factor for retroperitoneal hemorrhage-sheath
nsertion above the inferior epigastric artery (44–46). In
ddition, femoral angiography identifies the estimated 13%
f patients with nonfemoral artery sheath insertion for
hich VCD utilization is of unclear efficacy (Fig. 4) (20,43).
Figure 3 The Declining Rate of Vascular Complications
Over the past 5 years, major vascular complications have decreased among
patients undergoing percutaneous coronary intervention (PCI) in the Northern
New England Cardiovascular Disease Study Group. *Arterial injury and/or arte-
rial injury-related bleeding (n  36,631 patients undergoing PCI).
Figure 4 High-Risk Femoral Anatomy
Nonideal femoral anatomy includes patients with femoral arterial disease and she
the common femoral artery. Utilization of vascular closure devices in these situatiodentification of significant femoral arterial disease may
llow selective use of manual compression in situations
here implantation of an intravascular device may be
ssociated with an increased risk of complications (Table 1)
7,47). Furthermore, femoral angiography may be especially
mportant in the setting of multiple procedures at the same
emoral access site; there is limited data regarding the safety
f repeat access, and further study regarding the patholog-
cal and potential anatomical effects of repeat access with
ifferent devices is warranted (48–50).
ewer anticoagulation and antiplatelet strategies. Lower
oses of unfractionated heparin have almost certainly con-
ributed to the reduction in vascular complications (51).
ivalirudin also reduces the risk of bleeding complications
fter PCI compared with heparin  glycoprotein IIb/IIIa
nhibitors (41). Thus, changes in PCI-related pharmacology
ould be expected to decrease bleeding and vascular com-
lication rates up to 40%. Whether or not PCI pharmaco-
ogic changes may have preferentially benefited VCD or
anual compression requires further clarification via pro-
pective trials or subgroup analysis of recent trials (52).
evice improvements. The first VCD (Vasoseal) was a
ollagen device and the only VCD significantly associated
ith increased risk of vascular complications compared with
anual compression in 2 meta-analyses (29,33). The dom-
nant types of VCD in current practice are the suture-
ediated device (Perclose), the collagen-anchor-suture-
ediated device (Angio-Seal), and clip-mediated VCD
StarClose). The learning curve for each device may be
teep, and thus complication rates may have been higher in
he mid-to-late 1990s related to slow improvement in
perator proficiency (29,30,32). In addition, each of these
evices has undergone modification and simplification over
ime. For example, 1 longitudinal registry observed that the
se of the third generation of Angio-Seal VCD was
ertion outside
rrants further study.ath ins
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VCD Utilization and Outcomes October 23, 2007:1617–26ssociated with a 37% lower risk of vascular complications
ompared with the first Angio-Seal VCD (7).
ost concerns. One important consideration in determin-
ng the optimal role of VCDs is their cost. Although most
CDs currently cost on the order of $150 to $200, given the
arge volume of both diagnostic angiograms and PCI
rocedures at many U.S. hospitals (5), even such a modest
ncremental cost has the potential to substantially impact
atheterization laboratory and hospital budgets. Whether
heir utilization is cost effective depends on a variety of
actors including the frequency of vascular complications,
he impact of VCD use on the complication rate, and the
otential for VCD to substantially alter post-procedure
anagement patterns.
To date, several studies have examined the cost-
ffectiveness of vascular closure devices. The first such
nalysis was performed by Bos et al. (53). They used a
ecision analytic model to examine the potential cost-
ffectiveness of a collagen plug versus manual compression
or achieving hemostasis at arterial puncture sites. Although
hey concluded (based on fairly limited evidence at the time)
hat a collagen plug (either Vasoseal or Angio-Seal) could
educe complications by 50%, they estimated that use of a
CD would increase post-procedure costs by $135/patient
ith an overall cost-effectiveness ratio of $9,000 per vascular
omplication avoided. They concluded that this represented
relatively inefficient use of medical resources compared
ith other treatments. Whether this analysis is applicable to
contemporary U.S. catheterization laboratory population
s debatable, however. In particular, it is unclear whether the
ascular complication rates in their study (which were
erived from a very small number of early studies) are
omparable to those observed in current practice.
More recently, Resnic et al. (54) used a decision analytic
pproach to evaluate the potential cost savings associated
ith routine use of a collagen-suture plug (Angio-Seal)
ompared with manual compression. Data on specific com-
lication rates for the 2 strategies were derived from pooled
nalysis of published randomized clinical trials while costs
ssociated with various complications were derived from a
atched case-control study conducted at a single U.S.
cademic medical center. They concluded that compared
ith manual compression (using the Femostop device, Radi
edical, Uppsala, Sweden), routine use of the Angio-Seal
educed both complications and cost. Most of the cost
avings they projected were driven by reductions in vascular
omplications such as rebleeding, which they estimated to have
n attributable cost of $5,000 per event. It is important to
ote that the conclusions of this study were somewhat sensitive
o the cost of the compression strategy. In particular, VCD use
as no longer cost saving if the manual compression
trategy cost $66/patient (as might be anticipated with
anual compression alone). Thus, it is unclear whether
heir conclusions can be generalized to all U.S. hospitals.
oreover, these findings probably do not apply to patientsndergoing diagnostic catheterization alone where the ex- pected risk of vascular complications is substantially lower
han with PCI (4).
The strongest economic argument in favor of VCDs may
e their potential to convert an inpatient PCI procedure
nto an outpatient procedure (55,56). This possibility was
xplored in a small randomized clinical trial by Rickli et al.
57). They randomized 191 patients undergoing elective
CI at a single Swiss hospital to either a routine manual
ompression strategy or use of a suture-based closure device
Perclose). Patients assigned to manual compression under-
ent sheath removal 4 h after PCI and were kept at bed rest
vernight. In contrast, patients assigned to suture-mediated
losure underwent immediate sheath removal and were
mbulated after 4 h of bed rest. Although there were no
ignificant differences between the 2 strategies in terms of
ajor or minor vascular complications, use of suture-
ediated closure was associated with a 12-h reduction in
he post-PCI bed rest requirement (6.8 vs. 18.4 h) with
ssociated benefits in terms of groin pain, back pain, and
rinary problems. Their cost minimization analysis sug-
ested that despite the cost of the closure device (225€), this
as more than offset by reductions in hospital length of stay
nd physician time) with net savings of 70€/patient.
lthough similar savings might be achievable in a U.S.
etting as well, given the current U.S. reimbursement system
which may reimburse substantially more for an inpatient
CI procedure than a similar procedure performed on an
utpatient basis), many hospitals may actually lose substan-
ial revenue by adopting such a strategy.
What can we conclude from the available studies? First
nd foremost, there is no single answer to the question
hether VCDs are cost effective. The answer depends on a
arge number of factors, most of which are particular to the
ocal healthcare environment. For example, if a hospital
outinely utilizes adjuncts to manual compression (such as
he Femostop device or additional staff), it appears that by
educing vascular complications a VCD device might be
ost neutral or cost saving for the vast majority of patients.
owever, if the relevant comparator is true manual com-
ression without additional staff, the cost offset is probably
ot sufficient to fully offset device costs at the present time.
n this case, a more restrictive patient selection might be
ustified by which VCD use was reserved for those patients
t greatest risk for bleeding (38,40) or for patients where a
rolonged period of bed rest would lead to unacceptable
iscomfort or risk of complications. Finally, the major
conomic value of VCDs appears to be their potential to
onvert PCI from an inpatient to an outpatient procedure,
t least for select individuals judged to be at low risk for
oronary ischemic complications (55). Whether this strategy
ecomes accepted and viable within the U.S. health care
ystem will depend more on changes to the reimbursement
ystem and the associated financial incentives than on the
otential cost-effectiveness of the overall strategy, however.
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efinitive clinical trials. To date, there have been no
arge-scale randomized clinical trials comparing outcomes
ith VCD use with those with manual compression. Nor
ave there been large-scale trials pitting devices head-to-
ead to determine the possible superiority of 1 device over
nother. There are several factors that account for these
eficiencies in our current evidence base. First, from the
tandpoint of revenue, the VCD market represents a rela-
ively small component of the total interventional cardiology
arket (5). As such, the incentive for device companies to
ponsor expensive large-scale clinical trials is reduced. Sec-
nd, sheaths are pulled only after the effects of anticoagu-
ants have worn off for manual compression but are removed
mmediately after PCI when a VCD is used. Thus, any
linical trial comparing manual compression to VCD would
epresent a comparison of 2 alternative closure strategies as
ell as a direct comparison of closure efficacy. Additionally,
here have been no consistent standards for defining vascular
omplications, particularly hematoma formation (37). More
ecently, a consistent definition has been adopted as part of
he FDA approval process and that definition would need to
e the basis of any future randomized trials (10). These prior
imitations have led to the circumstances of a less-than-
ptimal evidence base to guide VCD use. If the results of a
arge randomized clinical trial establishing vascular out-
omes with VCD compared with manual compression
ndicated that rates of vascular complications were lower
ith VCD, however, such a study would provide a strong
mpetus for VCD use in routine clinical practice.
hallenges for expanded VCD utilization. Vascular clo-
ure devices decrease the time to ambulation, the time to
ischarge, and decrease complications for patients undergo-
ng diagnostic angiographic procedures (4): How can similar
enefits be shown for a broader group of patients? Two
Figure 5 Intravascular Versus Extravascular Closure Devices
New staple- and clip-mediated (StarClose or Angiolink) vascular closure devices ha
(Perclose). This may be especially significant in situations where minor femoral art
arterial disease).roups believed to be at high risk for VCD use have been
outinely excluded from the pivotal studies leading to VCD
pproval: patients undergoing PCI for acute myocardial
nfarction (58) and patients who have documented femoral
rterial disease or other peripheral vascular disease
8,20,40,47). Prior studies of PCI patients with clinically
mportant peripheral vascular disease have suggested an
nhanced relative risk of vascular complications of 40% to
9% with absolute rates of complications from 2.6% to 8.9%
7,40,59–62) (Fig. 4). There are only limited data regarding
se of VCDs in patients with vascular disease involving the
emoral artery (59,60). Whether use of an extravascular
CD could result in an overall reduction in PCI-related
ascular complications for high-risk populations such as
hose with femoral arterial disease is an intriguing concept
hat requires further study (49,60,62,63) (Fig. 5).
We believe that several studies should be performed
efore expanding VCD use for both diagnostic and PCI
atients. Several of these potential studies are enumerated in
he following text:
A randomized trial of VCD versus manual compression
among patients at high risk of vascular complications; if
major vascular complication rates with manual compres-
sion were expected in 5% of an enriched control
population (i.e., those with femoral disease [62] and/or
PCI for acute myocardial infarction [58,64]), a device
that incurred a 2% rate of major vascular complication
could be studied and shown to be superior to manual
compression (p  0.05) in a 1,000-patient randomized
trial.
Surveillance registries to identify high-risk patient sub-
sets and low-frequency adverse events; utilization of
post-marketing surveillance registries of 10,000 pa-
tients may be advantageous given the relatively low rate
of current vascular complications; this concept is directly
otential advantage of being “extravascular” with no anchor (Angio-Seal) or suture
en compromise would be clinically consequential (i.e., mild-moderate femoralve a p
ery lum
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frequency events in high-frequency procedures (i.e.,
drug-eluting stent thrombosis) (65); one advantage of
VCD studies is that major vascular complications occur
early and thus the design of these studies (as opposed to
drug-eluting stent thrombosis) might require only 30-
day patient follow-up; utilizing data from only 2001, the
ACC-NCDR provided the largest registry data so far on
VCD (4); expanding this study to the period 2003 to
2006 could provide even more convincing data on VCD
impact on complications for diagnostic and PCI patients
especially among subgroups for which there are current
cautions (Table 1).
Studies to enhance detection of complication risk; use of
a surrogate marker for clinically important vascular
complications could provide a marker for device and
manual compression complications (15); for example, a
smaller randomized trial might utilize routine 30-day
femoral arterial duplex ultrasound (15,66) to determine
whether issues of nonclinical vascular compromise war-
rant caution with staple, collagen, suture, or manual
closure methods.
t is clear from the first decade of experience with VCD use
hat outcomes in an individual patient reflect characteristics
f the patient, the operator, and the device. While a
onsiderable number of studies have identified “high”-risk
atient characteristics (40,44), there are fewer studies that
ave evaluated the role of the operator in contributing to
ascular complications. One criticism of the trials used to
btain FDA approval for a VCD is that the results reflect
nitial operator experience with the device, and in some
ases the initial experience with closure devices in general
32). Thus, the rates of device failure and device-associated
ascular complications in early studies may represent out-
omes from the steep portion of the “learning curve” of
CD experience. Studies have documented a “learning
urve” phenomenon associated with VCD use (26,62).
mportantly, in the study by Warren et al. (26), there was a
3-fold increase in device failure for the first 50 patients
reated with Angio-Seal compared with subsequent deploy-
ents (14% early learning curve failure rate vs. 3.5% later
xperience of nondeployments, p  0.009) (26). In the
tudy by Balzer et al. (62), the learning curve for technical
uccess with suture-based closure was even steeper and
onger (350 patients).
While not definitive, these data strongly suggest that
perator and programmatic expertise occurs only after
ubstantial VCD experience has accrued. If VCD utilization
s to achieve its maximum potential to improve clinical
utcomes, it will thus be imperative to provide the educa-
ional and practice opportunities to achieve a high level of
xpertise. This education must address more than a partic-
lar VCD device: excellent access technique as a part of a
uccessful VCD procedure cannot be overemphasized. It is
ifficult to determine what percentage of VCD failures are presult of suboptimal access technique, but expanding the
se of VCDs will most likely occur in the setting of
nhanced access skills.
oward a more ideal VCD. Although the Angio-Seal and
erclose devices, the 2 VCDs with the longest period of
ommercial availability, have both undergone significant
volution and improvement (7), closure failures with these
evices still occur. Moreover, the newest commercially
vailable closure device, StarClose, has not eliminated this
roblem. In the CLIP (CLosure In Percutaneous Proce-
ures) study, there was an 11% failure rate in the PCI arm
f the study (10). Closure failure may occur for a number of
easons independent of the VCD used. Clinical and treat-
ent factors, such as use of glycoprotein IIb/IIIa inhibitors
nd advanced age (40), will likely always challenge arterial
ccess management. Procedural factors such as multiple
ttempts to gain access, back wall sticks, and access sites
utside of the common femoral artery likely contribute to
losure failure (10). The challenge for successful VCD use
n these situations is substantial.
The patient factors influencing closure success notwith-
tanding, the “ideal” closure device remains to be developed.
hat would this device look like? 1) A single device capable
f providing successful closure for all patient and access site
natomical variations; 2) an atraumatic device without a
oreign body or vascular alteration of the femoral artery; and
) a simple-to-use device with95% procedural success and
ow cost. Access site closure with heat, delivered via ultra-
ound guidance, may be the closest approximation to the
deal VCD to date—an active closure with no potential
ompromise of the femoral artery (67). Unfortunately, the
herus device (Therus Corporation, Seattle, Washington)
as had limitations that have delayed its introduction into
linical practice. Further innovation will be required to
chieve the “ideal VCD” in the next decade.
onclusions
ver the past decade, our information base has improved; so
ave the devices, pharmacology, and techniques associated
ith VCD. Based upon these more recent data, should all
atients get a VCD? No—those with severe femoral arterial
isease and sheath insertion above the inferior epigastric
rtery may have a higher risk with VCD than manual
ompression (45). Should most patients undergoing femoral
rterial access get a VCD? For diagnostic cases, the answer
ay be “yes” based upon both decreased complication rates
nd improved time to ambulation (1,4,8,16,54). As outlined
n the preceding text, however, there are numerous sub-
roups of diagnostic patients for whom insufficient data are
vailable to make a clear recommendation. For PCI pa-
ients, contemporary data support a neutral effect on com-
lications in the setting of ongoing concerns regarding
evice costs. The ability to convert an inpatient PCI
rocedure to an outpatient procedure (without adversely
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October 23, 2007:1617–26 VCD Utilization and Outcomesmpacting hospital reimbursement) by use of a VCD would
argely overcome these financial concerns.
The second decade of VCD launches with a history that
s characterized by cautious adoption of this particular
echnology and frightening case reports of adverse experi-
nces (4,32). Fortunately, the studies of the past 5 years
eem to suggest that selected VCD technology not only
mproves time to hemostasis, but also reduces complications
t least in patients undergoing diagnostic cardiac catheter-
zation (4,33,54). Expanded use of VCD technology seems
ikely over the next decade as cost-effectiveness is demon-
trated with respect to reduction in complications; the driver
or this expanded use will be definitive trials in enriched
opulations, adoption of same-day PCI, mega-registries
ith information on high-risk subgroups, and improving
echnology/pharmacology/closure technique.
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